Advertisement Takeda, Monash enter research collaboration to tackle human gastrointestinal diseases - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

Takeda, Monash enter research collaboration to tackle human gastrointestinal diseases

Takeda Pharmaceutical, the Monash Institute of Pharmaceutical Sciences (MIPS) and Australia's Monash University have entered into a strategic research alliance to develop new medicines that address the unmet medical needs in gastroenterology.

The research alliance will focus on discovery, research and development of new drugs for some of the common and debilitating gastrointestinal diseases and disorders such as irritable bowel syndrome, abdominal pain, chronic itch, severe constipation and diarrhea.

Takeda will be responsible for funding the three-year research project and will allow scientists from MIPS and Takeda to jointly work to research the mechanisms that underlie these diseases and develop new approaches for their treatment.

The project will be lead by MIPS deputy director Nigel Bunnett together with Dr Daniel Poole, also from MIPS.

Bunnett said: "There is no cure for many gastrointestinal diseases and current treatments are either inadequate or have major side-effects.

"If we can understand the mechanisms that trigger these diseases we can go on to develop effective drugs to treat them.

"Monash possesses the expertise, technology and materials at its research facilities necessary to conduct drug discovery, research and preclinical pharmaceutical development activities into gastrointestinal diseases."

The research project will build on work by MIPS to better understand the causes of disorders of gastrointestinal function and sensation and could potentially lead to powerful therapies for digestive and sensory diseases.